LNTH

LANTHEUS HOLDINGS INC

Healthcare | Mid Cap

$1.12

EPS Forecast

$376.4

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-08-29

Lantheus’s Q2 2026: A $8 Billion Curveball and the Quiet Exit from Guidance

Lead: LNTH, EPS, and a deal that rewrites the playbook

Lantheus Holdings, Inc. (LNTH) reported second‑quarter 2026 results that look enough to move markets without demanding a calendar‑burning applause. Revenue came in at $388.2 million for the quarter, while GAAP diluted earnings per share (EPS) were $1.11 and adjusted EPS stood at $1.55. Both measures were modestly down versus the prior year’s Q2, where GAAP EPS was $1.12 and adjusted EPS was $1.57. In plain terms: the business didn’t collapse, but it didn’t accelerate either. EPS, EPS consensus, and revenue forecast readings will matter more than the headline numbers in the coming weeks as analysts parse what a sizeable strategic move—an all‑cash merger with Curium US Holdings LLC—means for LNTH’s earnings trajectory.

The deal that could redefine the chart for LNTH

The big drumbeat in the filing is the announced definitive merger with Curium. Under the terms, Curium US Holdings LLC will acquire all outstanding Lantheus shares for $102.50 per share in cash at closing, plus non‑transferable Contingent Value Rights (CVRs) that could deliver up to an additional $12.00 per share, contingent on milestones through 2030. In aggregate, the transaction contemplates up to about $114.50 per LNTH share and a total enterprise value around $8.0 billion.

CVRs function like a financial parachute for the acquirer and a gamble for LNTH shareholders: you get cash now, with upside if products hit milestones, which could meaningfully tilt the economics if the prognosticated milestones align with market uptake. The deal’s all‑cash nature underscores Curium’s confidence, but it also places the onus on closing risk, financing, and integration synergies—factors investors will scrutinize as the press release yields to the 8‑K detail dump.

The combination aims to create a radiopharmaceutical powerhouse spanning diagnostics and therapeutics across 70+ countries. The market will be watching for how this affects revenue forecast trajectories, product mix, and capital allocation discipline as the two firms blend portfolios and pipelines.

Guidance, confetti, and the quiet exit from 2026 forecasts

A notable strategic shift is the suspension of Lantheus’s previously issued full‑year 2026 financial guidance. The company also said it will not host a conference call in connection with its second‑quarter results. In practice, this signals a pause on forward projections while management focuses on closing the Curium transaction and realigning the business post‑deal. With revenue forecast visibility dimmed by the merger, investors should expect a period of heightened sensitivity to deal milestones, closing timing, and any regulatory or integration hurdles.

What this could portend for LNTH and sector peers

The LNTH move, if consummated, gives the radiopharmaceutical space a template for scale through consolidation. Expect peers to reevaluate pricing power, CVR mechanics, and the balance between cash funding versus stock considerations in deals with large, milestone‑driven components. For LNTH, the near‑term math hinges on:

  • Whether the CVRs are ultimately worth the risk premium priced into an all‑cash offer.
  • The extent to which synergy capture justifies the premium relative to standalone earnings trajectories.
  • How the absence of 2026 guidance affects equity risk premium and EPS risk in the back half of the year.
  • Operational integration costs, potential dilution from financing, and milestone pacing under the newly expanded portfolio.

From a sector lens, this is a reminder that the radiopharma space remains a capital‑intensive, milestone‑driven game where strategic bets—whether on product approvals, milestone milestones, or geographic reach—can reweight a company’s earnings narrative. The market will parse any earnings surprise elements in light of the deal’s timing and the ability to monetize Curium’s and Lantheus’s combined asset base.

Takeaways for investors and industry watchers

LNTH delivered a quarter with solid absolute revenue, but earnings per share metrics drifted modestly lower year over year. The strategic centerpiece—a cash deal valued at up to $8 billion with CVRs—could reshape LNTH’s earnings cadence and capital structure, depending on the deal’s closing and the milestones that unlock additional cash. The suspension of 2026 guidance adds a layer of uncertainty, effectively shifting investor focus toward the timeline of the closing, the operational plan post‑close, and the path to realizing any synergy benefits.

  • Ticker: LNTH
  • EPS: GAAP $1.11; Adjusted $1.55 for Q2 2026
  • Revenue: $388.2 million in Q2 2026
  • Deal value: up to $8.0 billion, all‑cash + CVRs
  • Milestones: CVRs contingent on performance through 2030
  • Guidance: no 2026 revenue or earnings forecast issued
  • Analysts’ view: EPS consensus and potential earnings surprise will hinge on deal progression and integration outcomes

Analysts and readers should monitor 8‑K filings for the precise terms of the Curium transaction, closing timelines, and any updates to CVR mechanics. The LNTH story is not just about quarterly numbers; it’s about balance sheets, the tempo of regulatory clearances, and whether the combination can unlock more than the sum of its radiopharmaceutical parts.